Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 19/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19558173 | 0.80 | CRBN (0.40) | DDB1CRBN | |
| SCHEMBL19532801 | 0.79 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL23052633 | 0.79 | CRBN (0.34) | DDB1CRBN | |
| SCHEMBL14680996 | 0.78 | CRBN (0.44) | DDB1CRBNALDH1A1CHRM2OPRM1 | |
| SCHEMBL19541966 | 0.77 | CRBN (0.39) | DDB1CRBN | |
| SCHEMBL21536712 | 0.77 | CRBN (0.39) | DDB1CRBN | |
| SCHEMBL6123578 | 0.77 | MAP3K14 (0.44) | DDB1CRBNTSHRTDP1 | |
| SCHEMBL22374247 | 0.75 | CRBN (0.38) | DDB1CRBN | |
| SCHEMBL23075112 | 0.71 | NPC1 (0.47) | ALDH1A1 | |
| SCHEMBL493044 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739326-B2 | RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739326-B2 | RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2023-08-29 | — | — | US | disclosed |
| US-11702399-B2 | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2023-07-18 | — | — | US | disclosed |
| US-11702399-B2 | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2023-07-18 | — | — | US | disclosed |
| US-11518746-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-12-06 | — | — | US | disclosed |
| US-20210395244-A1 | MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK) DEGRADATION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2021-12-23 | — | — | US | disclosed |
| US-11198677-B2 | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2021-12-14 | — | — | US | disclosed |
| US-11174271-B2 | 6-membered uracil isosteres | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-16 | — | — | US | disclosed |
| US-11168059-B2 | Amino sulfonyl compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-09 | — | — | US | disclosed |
| US-11124485-B2 | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-09-21 | — | — | US | disclosed |
| US-10017492-B2 | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2018-07-10 | — | — | US | disclosed |
| US-20180155319-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | UNIVERSITY OF SOUTHERN CALIFORNIA | 2018-06-07 | — | — | US | disclosed |
| US-20180155319-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | UNIVERSITY OF SOUTHERN CALIFORNIA | 2018-06-07 | — | — | US | disclosed |
| US-9981975-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-9809571-B2 | Deoxyuridine triphosphatase inhibitors | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809571-B2 | Deoxyuridine triphosphatase inhibitors | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170313676-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170313676-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2017-09-28 | — | — | US | disclosed |
| US-20160039788-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | UNIVERSITY OF SOUTHERN CALIFORNIA | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155319-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | DDB1 117/4885CRBN 3664/4885ALDH1A1 1486/4885 |
| US-11174271-B2 | 6-membered uracil isosteres | UNG, DUT, DPYD | DDB1 80/4885CRBN 3184/4885ALDH1A1 972/4885 |
| US-11168059-B2 | Amino sulfonyl compounds | DPYD, DNPEP, DUT | DDB1 33/4885CRBN 1595/4885ALDH1A1 2924/4885 |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MERTK, MAP3K15, MAP3K5 | DDB1 2375/4885CRBN 2245/4885ALDH1A1 2279/4885 |
| US-20210395244-A1 | MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK) DEGRADATION COMPOUNDS AND METHODS OF USE | MAP2K2, MAP2K1, MAP2K7 | DDB1 995/4885CRBN 1094/4885ALDH1A1 3186/4885 |
| US-10017492-B2 | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof | IL2, IL1B, IL5 | DDB1 3019/4885CRBN 3765/4885ALDH1A1 487/4885 |
| US-11739326-B2 | RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition | RUNX1, CXCL12, MITF | DDB1 453/4885CRBN 471/4885ALDH1A1 3515/4885 |
| US-11518746-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | DUT, DPYD, TYMP | DDB1 98/4885CRBN 2306/4885ALDH1A1 1672/4885 |
| US-11124485-B2 | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage | DPYD, DUT, TYMP | DDB1 108/4885CRBN 3608/4885ALDH1A1 966/4885 |
| US-20170313676-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | IL2, IL1B, IL5 | DDB1 3019/4885CRBN 3765/4885ALDH1A1 487/4885 |
| US-11198677-B2 | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage | DUT, DPYD, TYMP | DDB1 75/4885CRBN 3137/4885ALDH1A1 1484/4885 |
| US-11702399-B2 | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications | CYP4F11, WEE1, CYP51A1 | DDB1 4571/4885CRBN 4188/4885ALDH1A1 651/4885 |
| US-20160039788-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | DDB1 117/4885CRBN 3664/4885ALDH1A1 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.